Bruns Ingmar 4
4 · Zentalis Pharmaceuticals, Inc. · Filed Jan 9, 2026
Insider Transaction Report
Form 4
Bruns Ingmar
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2026-01-08+365,000→ 365,000 totalExercise: $2.84Exp: 2036-01-07→ Common Stock (365,000 underlying)
Footnotes (1)
- [F1]The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.